A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism
- 4 September 2001
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 135 (5) , 322-327
- https://doi.org/10.7326/0003-4819-135-5-200109040-00008
Abstract
The factor V Leiden mutation is a common genetic defect associated with an increased risk for venous thromboembolism. The clinical implications for asymptomatic carriers of this mutation and, consequently, the usefulness of screening families in which a proband has both the mutation and venous thromboembolism are unclear. To determine the incidence of venous thromboembolism in asymptomatic carriers of the factor V Leiden mutation. Prospective cohort study. University hospitals in the Netherlands. 470 asymptomatic carriers of the factor V Leiden mutation (234 men, 236 women; mean age, 43 years [range, 15 to 88 years]), 12 of whom were homozygous. Carriers were identified by screening the first-degree relatives (>15 years of age) of 247 symptomatic probands. Objectively diagnosed episodes of venous thromboembolism and the relationship between incidence and exposure to high-risk situations. Nine venous thromboembolic events were observed in 1564 observation-years, resulting in an annual incidence of 0.58% (95% CI, 0.26% to 1.10%). The incidence of spontaneous venous thromboembolism was 0.26% (CI, 0.07% to 0.65%) per year; 3.5% (CI, 0.1% to 17.8%) per episode of surgery, trauma, or immobilization; 0.0% (CI, 0.0% to 19.5%) per pregnancy; 1.8% (CI, 0.4% to 5.2%) per year of oral contraceptive use; and 2.9% (CI, 0.8% to 15.3%) per year of use of hormone replacement therapy. The absolute annual incidence of spontaneous venous thromboembolism in asymptomatic carriers of the factor V Leiden mutation is low and does not justify routine screening of the families of symptomatic patients.Keywords
This publication has 21 references indexed in Scilit:
- Incidence of Venous Thromboembolism in Families with Inherited ThrombophiliaThrombosis and Haemostasis, 1999
- Factor V:Q506Mutation-Resistance to Activated Protein C (APC): Clinical Implications with Respect to Family ScreeningSeminars in Thrombosis and Hemostasis, 1998
- The Incidence of Venous Thromboembolism in Family Members of Patients with Factor V Leiden Mutation and Venous ThrombosisAnnals of Internal Medicine, 1998
- Are we ready for factor V Leiden screening?The Lancet, 1996
- World distribution of factor V LeidenThe Lancet, 1995
- Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy MenNew England Journal of Medicine, 1995
- Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor VThe Lancet, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia StudyThe Lancet, 1993
- Deficiencies of Coagulation-Inhibiting and Fibrinolytic Proteins in Outpatients with Deep-Vein ThrombosisNew England Journal of Medicine, 1990